AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26983411 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous pedicle screw fixation at the fractured vertebra
Number of subjects: 32
Study 26983411 — intervention group
Group type: COMPARATOR
Intervention: Control group (no placement of pedicle screws into the fractured vertebra)
Number of subjects: 32
Study 24809233 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual administration of 3 mg tacrolimus powder for 15 min
Number of subjects: 18
Study 24809233 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal administration of 15 mg tacrolimus suppository
Number of subjects: 18
Study 24809233 — intervention group
Group type: COMPARATOR
Intervention: Oral administration of 7 mg tacrolimus capsules (Prograf)
Number of subjects: 18
Study 21594575 — intervention group
Group type: EXPERIMENTAL
Intervention: Huggy‐Puppy intervention (HPI)
Number of subjects: 104
Study 21594575 — intervention group
Group type: EXPERIMENTAL
Intervention: Revised Huggy‐Puppy intervention (HPI-r)
Number of subjects: 104
Study 21594575 — intervention group
Group type: COMPARATOR
Intervention: Waiting list comparison group (WL)
Number of subjects: 104
Study 19329465 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodontal therapy and oral hygiene instruction in the third trimester
Number of subjects: 83
Study 19329465 — intervention group
Group type: COMPARATOR
Intervention: No periodontal treatment (Control)
Number of subjects: 83
Study 17447869 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnotic intervention
Number of subjects: 124
Study 17447869 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral intervention
Number of subjects: 124
Study 17447869 — intervention group
Group type: COMPARATOR
Intervention: Placebo control intervention
Number of subjects: 124
Study 15177793 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantomime (P)
Number of subjects: 62
Study 15177793 — intervention group
Group type: EXPERIMENTAL
Intervention: Imitation (concurrent (CI) and delayed (DI))
Number of subjects: 62
Study 15177793 — intervention group
Group type: EXPERIMENTAL
Intervention: MMSE scores
Number of subjects: 62
Study 15177793 — intervention group
Group type: EXPERIMENTAL
Intervention: Patterns of apraxia
Number of subjects: 62
Study 11779723 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg once daily for 4 weeks
Number of subjects: 80
Study 11779723 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 9844957 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH treatment
Number of subjects: 15
Study 9844957 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal serum leptin in patients with depression
Number of subjects: 15
Study 9844957 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal cortisol secretion in patients with depression
Number of subjects: 15
Study 9844957 — intervention group
Group type: COMPARATOR
Intervention: No significant differences in plasma GH and ACTH
Number of subjects: 15
Study 9844957 — intervention group
Group type: COMPARATOR
Intervention: Correlation of serum leptin with BMI in controls
Number of subjects: 15
Study 9844957 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal leptin surge in young female patients
Number of subjects: 15
Study 9836109 — intervention group
Group type: COMPARATOR
Intervention: 3 MU alpha 2b-interferon
Number of subjects: 80
Study 9836109 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 MU alpha 2b-interferon
Number of subjects: 80
Study 9836109 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 MU alpha 2b-interferon in cirrhotic patients
Number of subjects: 80
Study 2564782 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium (0.92‐0.98 mg kg‐1) administered by continuous infusion or intermittent bolus doses
Number of subjects: 0
Study 2564782 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium (0.16‐0.18 mg kg‐1) administered by continuous infusion or intermittent bolus doses
Number of subjects: 0
Study 2564782 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving no neuromuscular blocking drugs
Number of subjects: 0
Study 606784 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-virus vaccines
Number of subjects: 253
Study 606784 — intervention group
Group type: COMPARATOR
Intervention: Split-product vaccines
Number of subjects: 253
Study 606784 — intervention group
Group type: EXPERIMENTAL
Intervention: All vaccine preparations
Number of subjects: 253
Study 31092248 — intervention group
Group type: EXPERIMENTAL
Intervention: Aligning headlines and main causal claims with the underlying evidence
Number of subjects: 312
Study 31092248 — intervention group
Group type: EXPERIMENTAL
Intervention: Inserting explicit statements/caveats about inferring causality
Number of subjects: 312
Study 31092248 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 312
Study 27831828 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline-based management (NAEPP guidelines)
Number of subjects: 143
Study 26112148 — intervention group
Group type: EXPERIMENTAL
Intervention: Heating and cooling combination therapy (OCH-S100), 10 treatments (15 min each) over 4 weeks, consisting of five cycles of heating/cooling therapy (max: 45 °C, min: 15 °C).
Number of subjects: 80
Study 26112148 — intervention group
Group type: COMPARATOR
Intervention: Sham therapy, 10 treatments (15 min each) over 4 weeks, consisting of five cycles of sham therapy (max: 1 °C above skin temperature, min: 1 °C below skin temperature).
Number of subjects: 80
Study 24156206 — intervention group
Group type: EXPERIMENTAL
Intervention: 8% arginine, calcium carbonate and 1,000 ppm fluoride dentifrice
Number of subjects: 86
Study 24156206 — intervention group
Group type: COMPARATOR
Intervention: 1,000 ppm fluoride dentifrice
Number of subjects: 86
Study 21711215 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified therapeutic community aftercare (MTC‐A)
Number of subjects: 76
Study 21711215 — intervention group
Group type: COMPARATOR
Intervention: Standard aftercare (C)
Number of subjects: 76
Study 19550192 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation-based curriculum received one month before assessment
Number of subjects: 69
Study 19550192 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group received the same curriculum three months later
Number of subjects: 69
Study 16408206 — intervention group
Group type: EXPERIMENTAL
Intervention: rHEPO (10,000 IU s.c. three times a week)
Number of subjects: 30
Study 16408206 — intervention group
Group type: EXPERIMENTAL
Intervention: rHEPO+G‐CSF (10,000 IU rHEPO s.c. three times a week + 300 mug G‐CSF s.c. twice a week)
Number of subjects: 30
Study 16408206 — intervention group
Group type: COMPARATOR
Intervention: rHEPO
Number of subjects: 30
Study 16408206 — intervention group
Group type: COMPARATOR
Intervention: rHEPO+G‐CSF
Number of subjects: 30
Study 15250845 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary counselling (3 sessions over 4 months)
Number of subjects: 189
Study 15250845 — intervention group
Group type: COMPARATOR
Intervention: Usual care (dietary assessment and pamphlets)
Number of subjects: 189
Study 11420777 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate 10 mg/day
Number of subjects: 314
Study 11420777 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 314
Study 9250230 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (n = 141) received antibiotic-related suggestions from an infectious disease fellow and a clinical pharmacist.
Number of subjects: 252
Study 9250230 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 111) did not receive antibiotic-related suggestions.
Number of subjects: 252
Study 9250230 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (n = 141)
Number of subjects: 252
Study 8099802 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg nizatidine
Number of subjects: 12
Study 8099802 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg nizatidine
Number of subjects: 12
Study 8099802 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg nizatidine
Number of subjects: 12
Study 8099802 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg pirenzepine
Number of subjects: 12
Study 8099802 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg nizatidine plus 100 mg pirenzepine
Number of subjects: 12
Study 8099802 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 3332556 — intervention group
Group type: EXPERIMENTAL
Intervention: Unopposed 17 beta-estradiol
Number of subjects: 144
Study 3332556 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential combination with progestagen
Number of subjects: 144
Study 3332556 — intervention group
Group type: COMPARATOR
Intervention: 24R,25-(OH)2D3
Number of subjects: 144
Study 3332556 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study 30244669 — intervention group
Group type: EXPERIMENTAL
Intervention: Active low-level laser therapy (LLLT)
Number of subjects: 78
Study 30244669 — intervention group
Group type: COMPARATOR
Intervention: Placebo low-level laser therapy (LLLT)
Number of subjects: 78
Study 30244669 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 78
Study 29884067 — intervention group
Group type: EXPERIMENTAL
Intervention: SPACE intervention (educator physical activity training, provision of portable play equipment, modified outdoor schedule of 4 × 30‐minute periods)
Number of subjects: 200
Study 29884067 — intervention group
Group type: EXPERIMENTAL
Intervention: SPACE intervention
Number of subjects: 200
Study 26934687 — intervention group
Group type: EXPERIMENTAL
Intervention: Ten 1-min high-intensity intervals (90% VO2 peak, 1 min recovery)
Number of subjects: 30
Study 26934687 — intervention group
Group type: EXPERIMENTAL
Intervention: Five 2-min high-intensity intervals (80-100% VO2 peak, 1 min recovery)
Number of subjects: 30
Study 26934687 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 23129105 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based body scan (n = 27)
Number of subjects: 55
Study 23129105 — intervention group
Group type: COMPARATOR
Intervention: Reading about natural history (control group, n = 28)
Number of subjects: 55
Study 23238504 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy (25 Gy in 5 fractions) and postoperative chemotherapy (5-fluorouracil and leucovorin)
Number of subjects: 278
Study 23238504 — intervention group
Group type: COMPARATOR
Intervention: TME alone (surgery group)
Number of subjects: 278
Study 23238504 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy
Number of subjects: 278
Study 23238504 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative chemotherapy
Number of subjects: 278
Study 20564352 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐IFN‐lambda at 1.5 or 3.0 microg/kg administered every 2 weeks or weekly for 4 weeks (Part 1)
Number of subjects: 56
Study 20564352 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly doses of PEG‐IFN‐lambda ranging from 0.5 to 2.25 microg/kg in combination with ribavirin (RBV) for 4 weeks (Part 2)
Number of subjects: 56
Study 20564352 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly PEG‐IFN‐lambda at 1.5 microg/kg in combination with RBV for 4 weeks (Part 3)
Number of subjects: 56
Study 20564352 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐IFN‐lambda with or without RBV for 4 weeks
Number of subjects: 56
Study 18304051 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care testing (POCT) for troponin I (cTnI) measurement
Number of subjects: 860
Study 18304051 — intervention group
Group type: COMPARATOR
Intervention: Central hospital laboratory testing (CHLT)
Number of subjects: 860
Study 16003290 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus
Number of subjects: 30
Study 12447009 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.125% dextrin sulfate (DS) gel
Number of subjects: 73
Study 12447009 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 73
Study 10359883 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical corticosteroids
Number of subjects: 12
Study 10359883 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 7738624 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy
Number of subjects: 1714
Study 2143592 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium
Number of subjects: 24
Study 2143592 — intervention group
Group type: COMPARATOR
Intervention: Beclomethasone
Number of subjects: 24
Study 550158 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoking
Number of subjects: 0
Study 550158 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin (prostaglandin synthesis inhibitor)
Number of subjects: 0
Study 31488213 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloprost 1 ng/kg/min and eptifibatide 0.5 μg/kg/min for 48 hours
Number of subjects: 24
Study 31488213 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 28941976 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined dietary docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA), and gamma‐linolenic acid (GLA) supplementation
Number of subjects: 31
Study 28941976 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 26721008 — intervention group
Group type: EXPERIMENTAL
Intervention: 5mg rosuvastatin
Number of subjects: 82
Study 26721008 — intervention group
Group type: COMPARATOR
Intervention: 10mg rosuvastatin
Number of subjects: 82
Study 22791299 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening programme using ambulant intermittent electrocardiogram (ECG) recording to detect silent AF
Number of subjects: 25000
Study 22791299 — intervention group
Group type: COMPARATOR
Intervention: Control group (no screening)
Number of subjects: 25000
Study 22791299 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening programme
Number of subjects: 25000
Study 22783713 — intervention group
Group type: EXPERIMENTAL
Intervention: Camel milk
Number of subjects: 28
Study 22783713 — intervention group
Group type: COMPARATOR
Intervention: Cow milk
Number of subjects: 28
Study 19736900 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg oxycodone administered intravenously over 2 minutes
Number of subjects: 12
Study 19736900 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg oxycodone administered intravenously over 15 minutes
Number of subjects: 12
Study 19736900 — intervention group
Group type: COMPARATOR
Intervention: 0 mg oxycodone administered intravenously
Number of subjects: 12
Study 17903627 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 29
Study 17903627 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stent (BMS)
Number of subjects: 29
Study 15553287 — intervention group
Group type: EXPERIMENTAL
Intervention: Flowable resin composite (Tetric Flow)
Number of subjects: 20
Study 15553287 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid resin composite (Z100)
Number of subjects: 20
Study 15553287 — intervention group
Group type: EXPERIMENTAL
Intervention: Packable resin composite (Solitaire 2)
Number of subjects: 20
Study 15553287 — intervention group
Group type: EXPERIMENTAL
Intervention: Organically modified ceramics‐ormocer (Admira)
Number of subjects: 20
Study 11575408 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil-desflurane anaesthesia
Number of subjects: 44
Study 11575408 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl-desflurane anaesthesia
Number of subjects: 44
Study 9231604 — intervention group
Group type: EXPERIMENTAL
Intervention: Prospective evaluations by trained clinical trial examiners
Number of subjects: 0
Study 9231604 — intervention group
Group type: COMPARATOR
Intervention: Retrospective surgical chart reviews
Number of subjects: 0
Study 7961576 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine treatment
Number of subjects: 18
Study 7961576 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol (previous studies)
Number of subjects: 18
Study 3127965 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxamniquine at 20 mg/kg
Number of subjects: 0
Study 3127965 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxamniquine at 30 mg/kg
Number of subjects: 0
Study 3127965 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxamniquine at 40 mg/kg
Number of subjects: 0
Study 3127965 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel at 20 mg/kg
Number of subjects: 0
Study 3127965 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel at 30 mg/kg
Number of subjects: 0
Study 3127965 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel at 40 mg/kg
Number of subjects: 0
Study 31451351 — intervention group
Group type: EXPERIMENTAL
Intervention: Amikacin liposome inhalation suspension (ALIS, 590 mg QD)
Number of subjects: 0
Study 31451351 — intervention group
Group type: COMPARATOR
Intervention: Tobramycin inhalation solution (TIS, 300 mg BID)
Number of subjects: 0
Study 31451351 — intervention group
Group type: EXPERIMENTAL
Intervention: Amikacin liposome inhalation suspension (ALIS)
Number of subjects: 0
Study 31451351 — intervention group
Group type: COMPARATOR
Intervention: Tobramycin inhalation solution (TIS)
Number of subjects: 0
Study 29145631 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin 550 mg twice daily for 3 days
Number of subjects: 28
Study 29145631 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 27062955 — intervention group
Group type: EXPERIMENTAL
Intervention: True Acupuncture (TA)
Number of subjects: 68
Study 27062955 — intervention group
Group type: COMPARATOR
Intervention: Sham Acupuncture (SA)
Number of subjects: 68
Study 25997527 — intervention group
Group type: EXPERIMENTAL
Intervention: GDM macrosomia group
Number of subjects: 60
Study 25997527 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 60
Study 23709655 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle modification (ILS)
Number of subjects: 301
Study 23709655 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 850 mg twice a day
Number of subjects: 301
Study 23709655 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 301
Study 20470299 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice daily icodextrin
Number of subjects: 28
Study 20470299 — intervention group
Group type: COMPARATOR
Intervention: Once daily icodextrin
Number of subjects: 28
Study 18986359 — intervention group
Group type: EXPERIMENTAL
Intervention: S/S genotype of HTTLPR polymorphism in 5-HTT gene
Number of subjects: 100
Study 18986359 — intervention group
Group type: EXPERIMENTAL
Intervention: 12/12 genotypes of VNTR polymorphism
Number of subjects: 100
Study 18986359 — intervention group
Group type: EXPERIMENTAL
Intervention: State and Trait Anxiety Inventory tests (STAI-I and STAI-II)
Number of subjects: 100
Study 16634988 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine with cognitive-behavioural weight loss treatment
Number of subjects: 73
Study 16634988 — intervention group
Group type: COMPARATOR
Intervention: Cognitive-behavioural weight loss treatment alone
Number of subjects: 73
Study 16634988 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine
Number of subjects: 73
Study 12830996 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive technique to evaluate flow‐mediated vasodilation on the brachial artery
Number of subjects: 0
Study 10795944 — intervention group
Group type: EXPERIMENTAL
Intervention: Subtype targeted intervention approach
Number of subjects: 4144
Study 10795944 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster analyses using the Pros, Cons, and Situational Temptations from the Transtheoretical Model
Number of subjects: 4144
Study 10795944 — intervention group
Group type: COMPARATOR
Intervention: Previous research on stage-tailored and individualized interventions
Number of subjects: 4144
Study 8815168 — intervention group
Group type: EXPERIMENTAL
Intervention: D-ribose (60 g daily for 7 days)
Number of subjects: 5
Study 8815168 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 1386652 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 2231
Study 1386652 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2231
Study 6436879 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-low yielding cigarette (0.1 mg nicotine) for 10 days
Number of subjects: 26
Study 6436879 — intervention group
Group type: COMPARATOR
Intervention: Usual brand cigarette
Number of subjects: 26
Study 31489621 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-fundal LNG-IUS insertion
Number of subjects: 92
Study 31489621 — intervention group
Group type: COMPARATOR
Intervention: Fundal LNG-IUS insertion
Number of subjects: 92
Study 28370266 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate 220 mcg dry powder inhalation
Number of subjects: 54
Study 28370266 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 26978751 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptococcus salivarius K12‐based probiotic complex during 30 days in combination with nasal douche
Number of subjects: 219
Study 26978751 — intervention group
Group type: COMPARATOR
Intervention: Nasal douche alone
Number of subjects: 219
Study 23954763 — intervention group
Group type: COMPARATOR
Intervention: Emotionally charged pictures (erotica, neutral, mutilation) presented in 4 blocks; physiological-emotional reactions assessed in the absence of pain and during pain modulation.
Number of subjects: 28
Study 23954763 — intervention group
Group type: COMPARATOR
Intervention: Emotional modulation of pain assessed during the presentation of emotionally charged pictures.
Number of subjects: 28
Study 23954763 — intervention group
Group type: COMPARATOR
Intervention: Nociceptive flexion reflex (NFR) evoked by suprathreshold electric stimulations.
Number of subjects: 28
Study 21369549 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Negative Pressure (CNP)
Number of subjects: 8
Study 21369549 — intervention group
Group type: COMPARATOR
Intervention: Sham CNP
Number of subjects: 8
Study 21369549 — intervention group
Group type: COMPARATOR
Intervention: Control (no shell or wrap)
Number of subjects: 8
Study 19373824 — intervention group
Group type: EXPERIMENTAL
Intervention: Well Woman Program (WWP)
Number of subjects: 0
Study 19373824 — intervention group
Group type: COMPARATOR
Intervention: Minimal Intervention (MI)
Number of subjects: 0
Study 17134946 — intervention group
Group type: EXPERIMENTAL
Intervention: Proportional assist ventilation (PAV)
Number of subjects: 6